High dose of budesonide (DrugBank: Budesonide)
9 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
66 | IgA nephropathy | 0 |
93 | Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] | 0 |
94 | Primary sclerosing cholangitis | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
98 | Eosinophilic gastrointestinal disease | 0 |
228 | Bronchiolitis obliterans | 0 |
299 | Cystic fibrosis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00728715 (ClinicalTrials.gov) | January 2004 | 31/7/2008 | Efficacy of Budesonide-Formoterol in Bronchiectasis | Clinical Efficacy and Safety of Budesonide and Formoterol in the Management of Non-Cystic Fibrosis Bronchiectasis | Bronchiectasis | Drug: budesonide-formoterol single inhaler;Drug: High dose of budesonide;Drug: A;Drug: B | Hospital General de Requena | Esteve Labs (Grant) | Completed | 18 Years | 80 Years | Both | 40 | N/A | Spain |